Evidence map›Paper›PMID 42254938›Full record

ArticleJTO clinical and research reports2026

Multidisciplinary Approach to Sexual Dysfunction in Persons With Lung Cancer-Spanish Lung Cancer Group Expert Consensus Statement.

Aylen Vanessa Ospina-Serrano, Constanza Maximiano-Alonso, Pau Guillén-Sentís, Beatriz Losada, Patricia Cruz-Castellanos, Rafael López-Castro, Begoña Campos-Balea, Eider Azkona-Uribelarrea, Ana Cardeña, Augusto Valdivia and 18 more

Abstract read
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Aylen Vanessa Ospina-SerranoDepartment of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Constanza Maximiano-AlonsoDepartment of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Pau Guillén-SentísDepartment of Medical Oncology, Institut Català Oncología Badalona, Barcelona, Spain.
Beatriz LosadaDepartment of Medical Oncology, Hospital Universitario Fuenlabrada, Madrid, Spain.
Patricia Cruz-CastellanosDepartment of Medical Oncology, Hospital General Universitario Ciudad Real, Ciudad Real, Spain.
Rafael López-CastroDepartment of Medical Oncology, Hospital Clínico Universitario de Valladolid, Vallodolid, Spain.
Begoña Campos-BaleaDepartment of Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain.
Eider Azkona-UribelarreaDepartment of Medical Oncology, Hospital Universitario Cruces, Baracaldo, Spain.
Ana CardeñaDepartment of Medical Oncology, Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
Augusto ValdiviaDepartment of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain.
Alejandro Olivares-HernándezDepartment of Medical Oncology, Hospital Universitario de Salamanca, Salamanca, Spain.
Ana Blasco-CordellatDepartment of Medical Oncology, Hospital General Universitario de Valencia, Valencia, Spain.
María Sereno-MoyanoDepartment of Medical Oncology, Hospital Universitario Infanta Sofía, Madrid, Spain.
Delfina Peralta-TancoDepartment of Clinical Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
Manuel DómineDepartment of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Raquel RomãoDepartment of Medical Oncology, Hospital de Santo António, Unidade Local de Saúde Santo António, Porto, Portugal.
Silvia Muñoz-BorrajoDepartment of Medical Oncology, Hospital General Granollers, Granollers, Spain.
Manuel Garcia-EspantaleonDepartment of Obstetrics and Gynecology, Hospital Universitario Puerta de Hierro Majadahonda, Universidad Autónoma de Madrid, Madrid, Spain.
Augusto Pereira-SánchezDepartment of Gynecology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Esaú Fernández-PascualDepartment of Urology, Hospital Universitario La Paz, Madrid, Spain.
Josep Torremadé-BarredaDepartment of Urology, Asociación Española de Urología, Madrid, Spain.
Angel Luis MontejoDepartment of Psychiatry, Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain.
Miren LarrazabalDepartment of Psychology, Lyx Instituto de Urología, Madrid, Spain.
Carlos de la Cruz Martin-RomoDepartment of Psychology, PROTEDIS, Madrid, Spain.
Raquel Alvarez-GarciaDepartment of Medical Oncology, Hospital Vall d'Hebrón, Barcelona, Spain.
Froilan SánchezDepartment of Family Medicine, Academia Española de Sexología y Medicina Sexual, Valencia, Spain.
Virginia CalvoDepartment of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Mariano Provencio-PullaDepartment of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sexual dysfunction (SD) is a common adverse effect of oncologic treatment; however, sexual health assessment is not routinely included in the follow-up of persons with lung cancer (LC). Methods: The Spanish Lung Cancer Group conducted a formal consensus process to develop recommendations for a multidisciplinary approach to SD in persons with LC. Mixed methods combining a modified Delphi technique and a nominal group process were used to guide the discussions on the selected topics. Results: The consensus process was conducted between May and October 2024. A panel of 28 Spanish experts-including medical oncologists, gynecologists, urologists, family physicians, sexologists, psychologists, one psychiatrist, and one oncology nurse-was convened to address the multidimensional aspects of sexuality. A 33-item questionnaire was developed for the voting process, which comprised two rounds followed by a final nominal group meeting. The threshold for agreement among experts was set at 85%. In cases in which scientific evidence was limited or controversial, recommendations were based on expert clinical experience. The primary topics addressed included patient education on SD, screening and follow-up strategies, the composition and role of the multidisciplinary team, referral criteria among team members, and both nonpharmacologic and pharmacologic management of SD. Conclusions: This document presents the suggestions developed through expert panel discussions and summarizes the available scientific evidence supporting them. Given the absence of specific guidelines addressing sexual health assessment through oncologic follow-up of people with LC, this consensus may help improve clinical care and quality of life for this population in real-world practice.

Indexed as

Cancer treatmentExpert consensusLung cancerSexual dysfunctionSurvivors

Identifiers

PMID42254938
PMCPMC13241640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.